Intellia Therapeutics
Intellia Therapeutics' revenue rose 16.9% to $68 million in fiscal 2025. Its operating margin was −651.7%, up from −923.1% a year earlier. Free cash flow was −$396 million. The diluted share count rose 9.6%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Intellia Therapeutics does
Intellia Therapeutics develops gene-editing medicines based on CRISPR, a tool that can cut and change DNA. It has no approved product. Its approach is to deliver the editing tool into the body using lipid nanoparticles, tiny fat bubbles, and aim for a one-time treatment given by a single intravenous infusion in an outpatient setting.
Its two lead candidates are in Phase 3 trials. Lonvo-z is for hereditary angioedema, a rare inherited condition that causes swelling attacks, and the company is preparing for a planned launch in the first half of 2027. Nex-z is for transthyretin amyloidosis, a disease in which a misfolded protein builds up in organs. Intellia says these are the first in vivo genome editing candidates in Phase 3.
Intellia works with partners, mainly Regeneron, and licenses technology from others. It plans to build its own sales and manufacturing capability.
Its biggest risks, as it describes them
- CRISPR gene editing has only recently been tested in people and may never lead to products it can sell.
- Clinical development is long, costly and uncertain, and trials could show safety problems.
- Negative public opinion and tighter regulation of gene editing could hurt it.
- Its products may not be accepted by doctors, patients or insurers.
- Patents of others or loss of licensed rights could hurt it.
Income statement
Intellia Therapeutics lost money in fiscal 2025: a net loss of $413 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 749 | 1,193 | 912 | 602 | 450 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | — | — | — | — | — |
| Current ratio | 6.1x | 9.6x | 8.7x | 5.8x | 5.1x |
| Quick ratio | 6.1x | 9.6x | 8.7x | 5.8x | 5.1x |
Cash flow
Projections
Project Intellia Therapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 14, 2025 and November 13, 2026, 1 insider bought $1.4 million of Intellia Therapeutics shares on the open market, and 7 insiders sold $2.1 million, $1.2 million of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 21, 2026 | John M LeonardPresident and CEO, Director | Sold plan | 2,785 | $13.00 | $36,205 | Form 4 |
| Aug 20, 2026 | John M LeonardPresident and CEO, Director | Sold plan | 19,890 | $12.60 | $250,614 | Form 4 |
| Jul 22, 2026 | Edward J Dulac IIIEVP, Chief Financial Officer | Sold | 8,111 | $11.25 | $91,249 | Form 4 |
| Jul 2, 2026 | Edward J Dulac IIIEVP, Chief Financial Officer | Sold plan | 4,677 | $18.00 | $84,186 | Form 4 |
| Jul 1, 2026 | Michael P DubeVP, Chief Accounting Officer | Sold | 2,641 | $16.78 | $44,316 | Form 4 |
| Mar 2, 2026 | James BastaEVP, General Counsel | Sold | 1,211 | $13.78 | $16,688 | Form 4 |
| Mar 2, 2026 | Eliana ClarkEVP, Chief Technical Officer | Sold | 607 | $13.78 | $8,364 | Form 4 |
| Jan 5, 2026 | Fred E CohenDirector | Bought | 150,000 | $9.35 | $1.4 million | Form 4 |
| Jan 5, 2026 | John M LeonardPresident and CEO, Director | Sold | 34,146 | $9.21 | $314,485 | Form 4 |
| Jan 5, 2026 | David LebwohlEVP, Chief Medical Officer | Sold | 11,903 | $9.21 | $109,627 | Form 4 |
| Jan 5, 2026 | James BastaEVP, General Counsel | Sold | 10,397 | $9.21 | $95,756 | Form 4 |
| Jan 5, 2026 | Eliana ClarkEVP, Chief Technical Officer | Sold | 9,515 | $9.21 | $87,633 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | −1,155.3% | −553.2% | −568.1% |
| Altman Z'' | 2.03 | −3.19 | −6.12 |
| Accruals ratio | −6.2% | −13.7% | −1.8% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Pass | Fail | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Fail | Fail | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Fail | Pass | Pass |
| F-score | — | — | — |
Compare
Put Intellia Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Intellia Therapeutics | FY25 | 16.9% | −651.7% | −585.0% | — | — | — | |
| Vir Biotechnology | FY25 | −7.6% | −699.2% | −578.5% | — | — | — | Compare |
| Recursion Pharmaceuticals | FY25 | 26.9% | −867.9% | −506.5% | −117.2% | — | 4 | Compare |
| CytomX Therapeutics | FY25 | −44.8% | −29.4% | −99.5% | — | — | — | Compare |
| MeiraGTx | FY25 | 144.6% | −130.2% | −61.7% | — | — | 3 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 16 | 26 | 30 | 43 | 58 | 33 | 52 | 36 | 58 | 68 |
| Revenue growth | — | 58.5% | 16.5% | 41.6% | 34.5% | −43.0% | 57.7% | −30.4% | 59.5% | 16.9% |
| Gross profit | — | — | 30 | 43 | 58 | 33 | — | — | — | — |
| Research and development | 32 | 68 | 89 | 108 | 150 | 230 | 420 | 435 | 466 | 389 |
| Operating income | −32 | −70 | −91 | −106 | −137 | −268 | −458 | −515 | −534 | −441 |
| Net income | −32 | −68 | −85 | −474 | −134 | −268 | −474 | −481 | −519 | −413 |
| Diluted EPS (US$) | −1.42 | −1.88 | −1.98 | −2.11 | −2.40 | −3.78 | −6.16 | −5.42 | −5.25 | −3.81 |
| Diluted shares (millions) | 22 | 36 | 43 | 47 | 56 | 71 | 77 | 89 | 99 | 108 |
| Cash flow | ||||||||||
| Cash from operations | 36 | −65 | −61 | −103 | −50 | −225 | −333 | −394 | −349 | −395 |
| Capital expenditure | 6 | 10 | 6 | 7 | 4 | 13 | 14 | 14 | 6 | 1 |
| Free cash flow | 30 | −75 | −68 | −110 | −54 | −238 | −347 | −408 | −355 | −396 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 7 | 15 | 17 | 15 | 20 | 47 | 91 | 134 | 154 | 80 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 273 | 341 | 314 | 280 | 597 | 749 | 1,193 | 912 | 602 | 450 |
| Debt incl. finance leases | — | — | — | — | — | — | — | — | — | — |
| Total assets | 299 | 376 | 347 | 334 | 676 | 1,294 | 1,520 | 1,301 | 1,191 | 842 |
| Total liabilities | 89 | 76 | 69 | 64 | 149 | 254 | 284 | 251 | 319 | 171 |
| Shareholders' equity | 210 | 301 | 278 | 270 | 527 | 1,040 | 1,236 | 1,050 | 872 | 671 |
| Margins and ratios | ||||||||||
| Gross margin | — | — | 100.0% | 100.0% | 100.0% | 100.0% | — | — | — | — |
| Operating margin | −195.2% | −266.3% | −298.6% | −246.8% | −235.5% | −810.4% | −879.0% | −1,420.5% | −923.1% | −651.7% |
| Net margin | −192.0% | −258.6% | −280.4% | −1,100.1% | −231.5% | −810.5% | −909.8% | −1,326.5% | −896.8% | −609.9% |
| Free cash flow margin | 181.7% | −288.6% | −222.2% | −255.3% | −92.2% | −719.4% | −665.5% | −1,124.9% | −612.8% | −585.0% |
| Rule of 40 (growth + FCF margin) | — | −230.1% | −205.6% | −213.7% | −57.7% | −762.4% | −607.8% | −1,155.3% | −553.2% | −568.1% |
| Return on capital | — | — | — | — | — | — | — | — | — | — |
| Return on equity | −33.5% | −26.5% | −29.5% | −173.1% | −33.7% | −34.2% | −41.7% | −42.1% | −54.0% | −53.5% |
| Return on assets | −16.6% | −20.0% | −23.6% | −139.1% | −26.6% | −27.2% | −33.7% | −34.1% | −41.7% | −40.6% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |